RT Journal Article
SR Electronic
T1 Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 427
OP 433
VO 36
IS 1
A1 JOEL ISOHOOKANA
A1 KIRSI-MARIA HAAPASAARI
A1 YLERMI SOINI
A1 PEETER KARIHTALA
YR 2016
UL http://ar.iiarjournals.org/content/36/1/427.abstract
AB Background: The role of the redox-regulating peroxiredoxin (Prx) enzymes I-VI in pancreatic carcinoma is poorly characterized. Materials and Methods: The expression of Prxs I, II, III, V and VI was immunohistochemically evaluated in benign pancreas and in 69 pancreatic adenocarcinoma samples. Results: Cytoplasmic Prx I expression was significantly greater in cancer cells than in benign pancreas (p=0.002) and Prx I expression in adenocarcinoma cells was associated with a larger tumour (p=0.005). Stronger cytoplasmic Prx III expression was associated with node negativity (p=0.007) and better tumor differentiation (p=0.033). Greater cytoplasmic Prx V expression was associated with smaller tumours (p=0.029) and negative nodal status (p=0.003). Among patients with T3-4 tumours, stronger intensity of cytoplasmic Prx I was associated with longer relapse-free survival (p=0.041). In patients with tumours of T3-4 class only, cytoplasmic Prx VI expression was associated with longer disease-free survival (p=0.0037). Conclusion: Peroxiredoxins appear to be promising prognostic factors in cases of pancreatic adenocarcinoma, and this may be related to their potential as tumour suppressors.